ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1393

Predictors of Panniculitis in Systemic Lupus Erythematosus

Ashika Odhav1, Michelle Petri2 and Hong Fang2, 1University of Missouri Kansas City School of Medicine, Kansas, MO, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Panniculitis is a rare, but devastating manifestation of SLE.  We examined associates of panniculitis in a large SLE cohort. 

Methods: 52 out of 2,149 SLE patients in the cohort had panniculitis (2.4%).  The mean age at last assessment was 49±15 years. The patients were 46% African-American, 46% Caucasian, and 96% female.  Other SLE manifestations were determined at baseline by history, physical examination, and chart review; patients were then seen quarterly in follow-up.

Results:

The table shows the association of demographics, SLE manifestations and serologies with panniculitis. Panniculitis was strongly associated with discoid lupus and leg ulcers.  It was also associated with serositis, seizures, myositis, alopecia, and vasculitis.  Proteinuria was significantly less frequent in those with panniculitis.

Association between Various Factors and Panniculitis in SLE

 

Characteristics/

Manifestations

Panniculitis (%, N=52)

No panniculitis

(%, N=2097)

Odds Ratio

(95% CI)

Adjusted P-value§

History of smoking

48.1

37.8

1.3 (0.7, 2.3)

0.34

Disability

40.4

21.8

2.1 (1.1, 3.7)

0.016

Malar rash

57.7

51.0

1.3 (0.7, 2.3)

0.41

Discoid

50.0

19.0

3.8 (2.1, 6.9)

<.0001

Photosensitivity

63.5

53.7

1.4 (0.8, 2.6)

0.22

Mouth ulcers

61.5

51.2

1.5 (0.9, 2.7)

0.15

Arthritis

80.8

73.5

1.2 (0.6, 2.5)

0.57

Serositis

67.3

48.9

2.0 (1.1, 3.7)

0.020

Proteinuria

28.9

44.3

0.4 (0.2, 0.8)

0.0062

Hematologic disorder

75.0

65.7

1.4 (0.8, 2.7)

0.27

ANA positivity

98.1

96.5

1.7 (0.2, 12.8)

0.59

Myositis

19.2

  7.7

2.3 (1.1, 4.9)

0.023

Alopecia

73.1

53.1

2.0 (1.0, 3.8)

0.040

Vasculitis

28.9

14.2

2.2 (1.2, 4.2)

0.012

Leg ulcers

17.3

  2.5

7.1 (3.2, 15.7)

<.0001

Seizure

19.2

  9.5

2.4 (1.2, 4.8)

0.019

Peripheral Neuropathy

11.5

  3.7

2.5 (1.0, 6.4)

0.046

Leukopenia

59.6

43.9

1.8 (1.0, 3.2)

0.044

Lupus Anticoagulant

26.0

27.2

0.9 (0.5, 1.7)

0.73

Low C3

46.2

55.6

0.6 (0.4, 1.1)

0.12

Low C4

36.5

48.3

0.6 (0.3, 1.1)

0.10

Increased ESR

82.7

74.9

1.4 (0.6, 3.0)

0.41

Anti- Sm

11.5

19.4

0.6 (0.2, 1.4)

0.20

Anti-DNA

63.5

63.0

1.0 (0.5, 1.7)

0.88

Anti-Ro

38.5

30.6

1.4 (0.8, 2.6)

0.21

Anti-La

15.4

12.9

1.3 (0.6, 2.8)

0.52

§ Adjusted for ethnicity, gender, age at last assessment, and duration of SLE at last assessment

 Conclusion: In contrast to photosensitive cutaneous lupus, panniculitis is not associated with anti-Ro, anti-La, or smoking.  It is strongly associated with discoid (discoid lesions often overlay panniculitis areas).  It is not associated with any serologic test, and, in fact, is less frequent in those with renal lupus. The impact of panniculitis has been unrecognized, with 40% becoming disabled due to it.


Disclosure:

A. Odhav,
None;

M. Petri,
None;

H. Fang,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-panniculitis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology